.Pharmacolibrary.Drugs.ATC.V.V09IA06 .Pharmacolibrary.Drugs.ATC.V.V09IA06| name: | Technetium99mtcArcitumomab | |
| ATC code: | V09IA06 | |
| route: | intravenous | |
| compartments: | 1 | |
| dosage: | 0.5 | mg |
| volume of distribution: | 3.5 | L |
| clearance: | 0.15 | L/h |
| other parameters in model implementation | ||
Technetium (99mTc) arcitumomab is a radiopharmaceutical agent composed of a murine monoclonal antibody (arcitumomab) labeled with the radionuclide technetium-99m. It binds to carcinoembryonic antigen (CEA) and is used in the diagnosis of colorectal cancer through gamma imaging to localize CEA-expressing tumors. It is not widely used today due to the development of more advanced imaging agents.
No peer-reviewed publications with detailed pharmacokinetic parameters (e.g., clearance, volume of distribution) for technetium (99mTc) arcitumomab in humans are available as of 2024-06. Dosing is reported to be typically intravenous, with imaging conducted 2–5 hours post-injection.